• Dr. Shengsheng Xu, Senior Scientist II, Bioanalytical Services, Frontage Laboratories, Inc.
• Dr. Ke Li, Senior Scientist I, Bioanalytical Services, Frontage Laboratories, Inc.
Registration link: https://register.gotowebinar.com/register/8388674901497093647
Date: June 30, 2021, Wed., 12:00 PM EDT
Abstract: Protein therapeutics have become more and more popular in recent years due to their high target specificity and relative low toxicity. The structural complexity of these biologics poses challenges to gold standard bioanalytical approach, as known as ligand bind assay (LBA), which is unable to detect any structural alterations happen on proteins. These potential structural changes on protein therapeutics are critical for pharmacokinetic (PK)/pharmacodynamics (PD) evaluation. On the other hand, protein biomarkers have entered into a new phase for drug discovery. The association between target protein biomarker and other endogenous proteins raises the concern for applying LBA based assay. LC-MS has emerged as a state-of-the-art technique to overcome this type of challenges in quantitation of protein therapeutics and protein biomarkers. This webinar will review the application of different LC-MS based approaches including bottom-up, top-down and middle-down. Case studies relevant to these approaches will also be presented.
Key Learning Objective:
• Bioanalytical Challenges & Approaches for protein therapeutics and biomarkers Who Should Attend:
• Bioanalytical method developers for protein therapeutics and biomarkers